VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA"))), an emerging leader in designing novel cancer therapies, today announced that the Company has moved into additional laboratory space at its existing R&D site in Heidelberg, Germany, based on a previously signed long-term lease agreement. The expansion enables the company to accommodate for currently planned team additions in its R&D department, the installation of laboratory equipment and the build-up of the final R&D infrastructure needed for planned development activities.

VERAXA is pursuing a growing portfolio of proprietary and partnered drug development programs from early, discovery stage toward early clinical development. At the heart of VERAXA’s R&D activities is the Company’s novel BiTAC strategy and its application to drive a portfolio of BiTAC-TCE and BiTAC-ADC development programs. The BiTAC therapeutic strategy is designed to unlock a new level of precision in cancer treatment by using two complementary precursors and enabling a tumor-restricted activation of the desired therapeutic effect.